证券代码：002669 证券简称：康达新材 康达新材料（集团）股份有限公司 投资者关系活动记录表 编号：2025-006 | | ■特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 银河证券：靳学侠；东兴证券：李科融；中原证券：顾敏豪； | | | 东方财富证券：朱晋潇；东北证券：濮阳；上海华邻资产：郭晋； | | 参与单位名称及 | 上海海能投资：王瑞、徐习瑶；四川大决策投资：龚晓豹、罗雅静； | | 人员姓名 | 上海弈术投资：孙宏廷；上海远翰基金：刘月茹；上海尚欣投资：宋 | | | 明；上海睿沣私募基金：丁颖；北京俊远投资：梁阳平；约调研&投关 | | | 易：曹田。 | | 时间 | 年 月 日 2025 7 8 10:00—11:30 | | 地点 | 上海市浦东新区五星路 707 弄御河企业公馆 A 区 3 号楼公司会议室 | | 上市公司接待人 | 副总经理、董事会秘书：沈一涛；投资者关系专员：安琪 | | 员姓名 | | | | 董事会秘书沈一涛 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the company's stock will outperform the benchmark index by more than 20% over the next 6-12 months [2][6]. Core Views - The company has faced challenges in its zeolite and pharmaceutical segments due to weak downstream demand, but there is optimism regarding the growth potential from its various new material developments [4][9]. - The financial performance for 2024 shows a total revenue of RMB 3.693 billion, a decrease of 14.22% year-on-year, and a net profit attributable to shareholders of RMB 246 million, down 67.72% year-on-year [4][10]. - The report highlights the company's ongoing research and development efforts and the successful progress in new materials, which are expected to drive long-term growth [9][12]. Financial Summary - For 2024, the company reported total revenue of RMB 36.93 billion, with a significant decline in net profit to RMB 2.46 billion, reflecting a 67.72% decrease compared to the previous year [4][10]. - The first quarter of 2025 saw a revenue drop of 8.17% to RMB 861.23 million, with a net profit decrease of 18.76% to RMB 79.87 million [12]. - The earnings per share (EPS) estimates for 2025, 2026, and 2027 are projected to be RMB 0.39, RMB 0.48, and RMB 0.56 respectively, with corresponding price-to-earnings (PE) ratios of 28.4, 23.1, and 19.6 [6][8]. Business Segment Performance - The functional materials segment generated RMB 30.19 billion in revenue for 2024, down 10.30% year-on-year, with a gross margin of 39.96% [9]. - The company has maintained its leading position in high-end liquid crystal monomer materials and has seen good development in OLED materials, while also making progress in semiconductor manufacturing materials [9][12]. - The life sciences and pharmaceutical business experienced a revenue decline of 28.65% to RMB 6.29 billion in 2024, although the gross margin improved to 38.16% [9]. Future Outlook - The company is expected to expand its production capacity in functional materials, with the first phase of the Penglai project set to gradually come online in the first half of 2025 [9]. - The report emphasizes the potential for growth in various new materials, including applications in the petrochemical sector and advancements in OLED and semiconductor materials [9][12].